Altevax is developing a powerful pioneering immunotherapy technology against cancer and infectious diseases. Its patented melanin-based technology has been proven in pre-clinical trials to boost an antigen-specific immune response with Cytotoxic T-lymphocytes (CD8+ Killer T cells), the body’s most powerful defenders. The Altevax immunotherapy technology works with a wide range of peptides. The Altevax technology is complementary to other anti-cancer immune technologies, such as anti PD1s.
Altevax is developing an immunotherapy against glioblastoma, currently in advanced pre-clinical development, with Phase 1/2a expected in early 2023.
Altevax's partnership with Assistance Publique Hôpitaux de Paris and other research institutions enables it to leverage their resources and accelerate clinical trials.
Altevax is developing an immunotherapy against glioblastoma, currently in advanced pre-clinical development, with Phase 1/2a expected in early 2023.
Altevax's partnership with Assistance Publique Hôpitaux de Paris and other research institutions enables it to leverage their resources and accelerate clinical trials.
Location: France, Ile-de-France, Paris
Employees: 1-10
Founded date: 2016